Princeton, NJ, August 21, 2023 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has completed its key go/no go criteria enabling the start of the GLP Tox package with iQ-007, a novel anticonvulsant compound.
iQure is pleased to announce that it has completed two additional iQ-007 studies. First, a CaCo-2 test was performed demonstrating the high permeability of the compound and the lack of interaction with transporters, thereby increasing the drug ability of the compound. Second, a Cytotoxicity test was performed to confirm the initial results of lack of cytotoxic behavior of the compound. “With these positive results, the final go/no-go criteria has been achieved and we will now move full speed ahead with our main toxicology studies, beginning next month with the first Maximum Tolerated Dose (MTD) and two-week toxicology study in rats, which is an important step towards IND, scheduled for Q3 2024,” said Henk de Wilde, iQure Pharma’s Chief Operating Officer.
About iQure Pharma
iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.
Comments